Nielsen inks new beauty market agreement with the NPD Group
NEW YORK — Nielsen has teamed up with the NPD Group, a global information company, to jointly produce the quarterly U.S. Beauty Cross Channel Monitor.
The report reviews the U.S. beauty market performance, providing a market view spanning both the prestige and mass retail channels.
“The new agreement allows Nielsen and NPD to offer clients an unparalleled depth of insight and actionable intelligence,” stated John Lewis, president, Americas, Nielsen. “This will enable clients to make more informed business decisions and capitalize on new market opportunities.”
“We are committed to delivering the best information, insights, and solutions for our clients in all of the industries we serve,” added Karyn Schoenbart, president and COO, NPD. “We look forward to collaborating with Nielsen on this critical overview of the beauty marketplace.”
The Beauty Cross Channel Monitor will combine Nielsen and NPD point-of-sale data across food, drug, prestige department stores, and all retail outlets combined, providing a read on sales and performance for all beauty categories including dollar sales, unit sales and average retail price, in addition to a ranking of the top 75 to 100 brands.
The two organizations have worked together closely to create more refined product definitions, creating a more comprehensive view of product performance. This will allow brand marketers to better evaluate the performance of categories, segments and brands across major beauty distribution channels to better understand and respond to new U.S. beauty market opportunities, the companies stated.
This is the second market information agreement between Nielsen and the NPD Group in 2014. The two firms are collaborating in the offices supplies market. As part of that arrangement, Nielsen is serving as NPD’s preferred analytics partner for NPD clients in the office supplies market.
Supervalu announces election of new board members
MINNEAPOLIS — Supervalu has elected Frank (Terry) Savage and Mathew Pendo to its board of directors.
Savage and Pendo were both appointed to the board as designees of Symphony Investors, a Cerberus Capital Management-led investor consortium, under the terms of the tender offer agreement entered into with Symphony Investors and Cerberus in connection with Supervalu’s sale of five banners to an affiliate of Symphony Investors. Symphony Investors owns approximately 20.9% of Supervalu’s outstanding common stock.
Savage is currently a senior advisor to Lazard and the former vice chairman of U.S. Investment Banking at Lazard.
Pendo is currently a managing director at Sandler O’Neill Partners, a boutique investment banking firm focused on the financial services industry.
The board now has 11 members, nine of whom are independent directors under the New York Stock Exchange listing standards.
FDA approves first HPV test for cervical cancer screening
SILVER SPRING, Md. — The Food and Drug Administration on Thursday approved a human papillomavirus DNA test for women 25 years of age and older that can be used alone to help health care professionals assess the need for a woman to undergo additional testing for cervical cancer. The Cobas HPV test is the first and only HPV test approved for primary screening in the United States.
The test uses a sample of cervical cells to specifically identify HPV 16 and HPV 18, while also detecting 12 other types of high-risk HPVs.
“Today’s approval offers women and physicians a new option for cervical cancer screening,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health at the FDA’s Center for Devices and Radiological Health. “Roche Diagnostics conducted a well-designed study that provided the FDA with a reasonable assurance of the safety and effectiveness when used as a primary screening tool for cervical cancer.”
Based on results of the Cobas HPV test, women who test positive for HPV 16 or HPV 18 should have a colposcopy, an exam that uses a device to illuminate and magnify the cervix so a physician can observe the cervical cells. Women who test positive for one or more of the 12 other high-risk HPV types should have a Pap test to determine the need for a colposcopy.
The Cobas HPV test is manufactured by Roche Molecular Systems, which is based in Pleasanton, Calif.